Cefadroxil Capsules, USP
DESCRIPTION
Cefadroxil capsules contain the following inactive ingredients: Lactose monohydrate, magnesium stearate, FD&C Blue No.1, D&C Red No.28, FD&C Red No. 40, titanium dioxide, gelatin, sodium lauryl sulphate, and edible black ink (black iron oxide).
CLINICAL PHARMACOLOGY
Microbiology
Susceptibility tests
Diffusion Techniques
| ≥ 18 | (S) Susceptible |
| 15–17 | (I) Intermediate |
| ≤ 14 | (R) Resistant |
| Staphylococcus aureus ATCC 25923 | 29–37 |
| Escherichia coli ATCC 25922 | 17–22 |
Dilution Techniques
INDICATIONS AND USAGE
CONTRAINDICATIONS
WARNINGS
PRECAUTIONS
General
Information for Patients
Drug/Laboratory Test Interactions
Carcinogenesis, Mutagenesis, Impairment of Fertility
Pregnancy
Labor and Delivery
Nursing Mothers
Pediatric Use
Geriatric Use
ADVERSE REACTIONS
Gastrointestinal
Hypersensitivity
Other
OVERDOSAGE
DOSAGE AND ADMINISTRATION
Adults
Children
Renal Impairment
| 0-10 mL/min | 36 hours |
| 10-25 mL/min | 24 hours |
| 25-50 mL/min | 12 hours |
HOW SUPPLIED
REFERENCES
- National Committee for Clinical Laboratory Standards, Approved Standard, Performance Standards for Antimicrobial Disk Susceptibility Test, 4th Edition. Vol. 10 (7): M2-A4, Villanova, PA, April, 1990.
- National Committee for Clinical Laboratory Standards, Approved Standard: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 2nd Edition, Vol. 10(8): M7-A2, Villanova, PA, April, 1990.
PACKAGE LABEL
CEFADROXIL 500 MG LABEL IMAGE